|
1
|
Manfrè V, Chatzis LG, Cafaro G, Fonzetti
S, Calvacchi S, Fulvio G, Navarro Garcia IC, La Rocca G, Ferro F,
Perricone C, et al: Sjögren's syndrome: One year in review 2022.
Clin Exp Rheumatol. 40:2211–2224. 2022.
|
|
2
|
Stefanski AL, Tomiak C, Pleyer U, Dietrich
T, Burmester GR and Dörner T: The diagnosis and treatment of
Sjögren's syndrome. Dtsch Arztebl Int. 114:354–361. 2017.PubMed/NCBI
|
|
3
|
Koh JH, Park Y, Lee J, Jeon H, Moon SJ,
Kim YH, Min JK, Park SH and Kwok SK: Long-term outcome of
interstitial lung disease in patients with primary Sjögren's
syndrome: A retrospective observational study. Korean J Intern Med.
40:148–159. 2025. View Article : Google Scholar :
|
|
4
|
Lessard CJ, Li H, Adrianto I, Ice JA,
Rasmussen A, Grundahl KM, Kelly JA, Dozmorov MG, Miceli-Richard C,
Bowman S, et al: Variants at multiple loci implicated in both
innate and adaptive immune responses are associated with Sjögren's
syndrome. Nat Genet. 45:1284–1292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Z and Chu A: Sjögren's syndrome and
viral infections. Rheumatol Ther. 8:1051–1059. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kapsogeorgou EK and Tzioufas AG:
Interaction of human salivary gland epithelial cells with B
lymphocytes: Implications in the pathogenesis of Sjögren's
syndrome. Mediterr J Rheumatol. 31:424–426. 2020. View Article : Google Scholar
|
|
7
|
Haacke EA, Bootsma H, Spijkervet FKL,
Visser A, Vissink A, Kluin PM and Kroese FGM: FcRL4+
B-cells in salivary glands of primary Sjögren's syndrome patients.
J Autoimmun. 81:90–98. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka Y, Sotome T, Inoue A, Mukozu T,
Kuwabara T, Mikami T, Kowhi-Shigematsu T and Kondo M: SATB1
conditional knockout results in Sjögren's syndrome in mice. J
Immunol. 199:4016–4022. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Blokland SC, van Helden-Meeuwsen CG,
Wierenga-Wolf AF, Drexhage HA, Hooijkaas H, van de Merwe JP and
Versnel MA: Two different types of sialoadenitis in the NOD- and
MRL/lpr mouse models for Sjögren's syndrome: A differential role
for dendritic cells in the initiation of sialoadenitis? Lab Invest.
80:575–585. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian Y, Yang H, Liu N, Li Y and Chen J:
Advances in pathogenesis of Sjögren's syndrome. J Immunol Res.
2021:59282322021. View Article : Google Scholar
|
|
11
|
Ramos-Casals M, Brito-Zerón P, Bombardieri
S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE,
Hernandez-Molina G, Kocher A, et al: EULAR recommendations for the
management of Sjögren's syndrome with topical and systemic
therapies. Ann Rheum Dis. 79:3–18. 2020. View Article : Google Scholar
|
|
12
|
Dorjsembe B, Joo H, Nho C, Ham J and Kim
JC: Aruncus dioicus var. kamtschaticus extract ameliorates
psoriasis-like skin inflammation via Akt/mTOR and JAK2/STAT3
signaling pathways in a murine model. Nutrients. 14:50942022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roy T, Banang-Mbeumi S, Boateng ST, Ruiz
EM, Chamcheu RN, Kang L, King JA, Walker AL, Nagalo BM, Kousoulas
KG, et al: Dual targeting of mTOR/IL-17A and autophagy by fisetin
alleviates psoriasis-like skin inflammation. Front Immunol.
13:10758042023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah M, Edman MC, Janga SR, Shi P,
Dhandhukia J, Liu S, Louie SG, Rodgers K, Mackay JA and
Hamm-Alvarez SF: A rapamycin-binding protein polymer nanoparticle
shows potent therapeutic activity in suppressing autoimmune
dacryoadenitis in a mouse model of Sjögren's syndrome. J Control
Release. 171:269–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shan J, Jin H and Xu Y: T cell metabolism:
A new perspective on Th17/treg cell imbalance in systemic lupus
erythematosus. Front Immunol. 11:10272020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heitman J, Movva NR and Hall MN: Targets
for cell cycle arrest by the immunosuppressant rapamycin in yeast.
Science. 253:905–909. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sabatini DM, Erdjument-Bromage H, Lui M,
Tempst P and Snyder SH: RAFT1: A mammalian protein that binds to
FKBP12 in a rapamycin-dependent fashion and is homologous to yeast
TORs. Cell. 78:35–43. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mita MM, Mita A and Rowinsky EK: Mammalian
target of rapamycin: A new molecular target for breast cancer. Clin
Breast Cancer. 4:126–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keith CT and Schreiber SL: PIK-related
kinases: DNA repair, recombination, and cell cycle checkpoints.
Science. 270:50–51. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang M, Lu Y, Piao W and Jin H: The
translational regulation in mTOR pathway. Biomolecules. 12:8022022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YC and Guan KL: mTOR: A pharmacologic
target for autophagy regulation. J Clin Invest. 125:25–32. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Y, Wang H, Qu T, Luo J, An P, Ren F,
Luo Y and Li Y: mTORC2: A multifaceted regulator of autophagy. Cell
Commun Signal. 21:42023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar
|
|
24
|
Nunnery SE and Mayer IA: Targeting the
PI3K/AKT/mTOR pathway in hormone-positive breast cancer. Drugs.
80:1685–1697. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yilmaz OH and Morrison SJ: The PI-3kinase
pathway in hematopoietic stem cells and leukemia-initiating cells:
A mechanistic difference between normal and cancer stem cells.
Blood Cells Mol Dis. 41:73–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korets SB, Czok S, Blank SV, Curtin JP and
Schneider RJ: Targeting the mTOR/4E-BP pathway in endometrial
cancer. Clin Cancer Res. 17:7518–7528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Magnuson B, Ekim B and Fingar DC:
Regulation and function of ribosomal protein S6 kinase (S6K) within
mTOR signalling networks. Biochem J. 441:1–21. 2012. View Article : Google Scholar
|
|
28
|
Alves CL and Ditzel HJ: Drugging the
PI3K/AKT/mTOR pathway in ER+ breast cancer. Int J Mol Sci.
24:45222023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grabiner BC, Nardi V, Birsoy K, Possemato
R, Shen K, Sinha S, Jordan A, Beck AH and Sabatini DM: A diverse
array of cancer-associated MTOR mutations are hyperactivating and
can predict rapamycin sensitivity. Cancer Discov. 4:554–563. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marnett LJ: Lipid peroxidation-DNA damage
by malondialdehyde. Mutat Res. 424:83–95. 1999.PubMed/NCBI
|
|
31
|
Lai ZW, Kelly R, Winans T, Marchena I,
Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, et al:
Sirolimus in patients with clinically active systemic lupus
erythematosus resistant to, or intolerant of, conventional
medications: A single-arm, open-label, phase 1/2 trial. Lancet.
391:1186–1196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shortman K and Liu YJ: Mouse and human
dendritic cell subtypes. Nat Rev Immunol. 2:151–161. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sukhbaatar N, Hengstschläger M and
Weichhart T: mTOR-mediated regulation of dendritic cell
differentiation and function. Trends Immunol. 37:778–789. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sathaliyawala T, O'Gorman WE, Greter M,
Bogunovic M, Konjufca V, Hou ZE, Nolan GP, Miller MJ, Merad M and
Reizis B: Mammalian target of rapamycin controls dendritic cell
development downstream of Flt3 ligand signaling. Immunity.
33:597–606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van de Laar L, Buitenhuis M, Wensveen FM,
Janssen HL, Coffer PJ and Woltman AM: Human CD34-derived myeloid
dendritic cell development requires intact phosphatidylinositol
3-kinase-protein kinase B-mammalian target of rapamycin signaling.
J Immunol. 184:6600–6611. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schmitz F, Heit A, Dreher S, Eisenächer K,
Mages J, Haas T, Krug A, Janssen KP, Kirschning CJ and Wagner H:
Mammalian target of rapamycin (mTOR) orchestrates the defense
program of innate immune cells. Eur J Immunol. 38:2981–2992. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haidinger M, Poglitsch M, Geyeregger R,
Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Hörl WH, Säemann MD
and Weichhart T: A versatile role of mammalian target of rapamycin
in human dendritic cell function and differentiation. J Immunol.
185:3919–3931. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Katholnig K, Linke M, Pham H,
Hengstschläger M and Weichhart T: Immune responses of macrophages
and dendritic cells regulated by mTOR signalling. Biochem Soc
Trans. 41:927–933. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Auffray C, Sieweke MH and Geissmann F:
Blood monocytes: Development, heterogeneity, and relationship with
dendritic cells. Annu Rev Immunol. 27:669–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi C and Pamer EG: Monocyte recruitment
during infection and inflammation. Nat Rev Immunol. 11:762–774.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Italiani P and Boraschi D: From monocytes
to M1/M2 macrophages: Phenotypical vs. functional differentiation.
Front Immunol. 5:5142014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shalova IN, Lim JY, Chittezhath M,
Zinkernagel AS, Beasley F, Hernández-Jiménez E, Toledano V,
Cubillos-Zapata C, Rapisarda A, Chen J, et al: Human monocytes
undergo functional re-programming during sepsis mediated by
hypoxia-inducible factor-1α. Immunity. 42:484–498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chung YH, Kim DH and Lee WW: Monosodium
urate crystal-induced pro-interleukin-1β production is
post-transcriptionally regulated via the p38 signaling pathway in
human monocytes. Sci Rep. 6:345332016. View Article : Google Scholar
|
|
44
|
Weichhart T, Costantino G, Poglitsch M,
Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH,
Hengstschläger M, et al: The TSC-mTOR signaling pathway regulates
the innate inflammatory response. Immunity. 29:565–577. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rauh MJ, Ho V, Pereira C, Sham A, Sly LM,
Lam V, Huxham L, Minchinton AI, Mui A and Krystal G: SHIP represses
the generation of alternatively activated macrophages. Immunity.
23:361–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Araki K, Ellebedy AH and Ahmed R: TOR in
the immune system. Curr Opin Cell Biol. 23:707–715. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Linke M, Pham HT, Katholnig K, Schnöller
T, Miller A, Demel F, Schütz B, Rosner M, Kovacic B, Sukhbaatar N,
et al: Chronic signaling via the metabolic checkpoint kinase mTORC1
induces macrophage granuloma formation and marks sarcoidosis
progression. Nat Immunol. 18:293–302. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Panwar V, Singh A, Bhatt M, Tonk RK,
Azizov S, Raza AS, Sengupta S, Kumar D and Garg M: Multifaceted
role of mTOR (mammalian target of rapamycin) signaling pathway in
human health and disease. Signal Transduct Target Ther. 8:3752023.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang R, Dillon CP, Shi LZ, Milasta S,
Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger
J and Green DR: The transcription factor Myc controls metabolic
reprogramming upon T lymphocyte activation. Immunity. 35:871–882.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kusaba H, Ghosh P, Derin R, Buchholz M,
Sasaki C, Madara K and Longo DL: Interleukin-12-induced
interferon-gamma production by human peripheral blood T cells is
regulated by mammalian target of rapamycin (mTOR). J Biol Chem.
280:1037–1043. 2005. View Article : Google Scholar
|
|
51
|
Waickman AT and Powell JD: mTOR,
metabolism, and the regulation of T-cell differentiation and
function. Immunol Rev. 249:43–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mafi S, Mansoori B, Taeb S, Sadeghi H,
Abbasi R, Cho WC and Rostamzadeh D: mTOR-mediated regulation of
immune responses in cancer and tumor microenvironment. Front
Immunol. 12:7741032022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Delgoffe GM, Kole TP, Cotter RJ and Powell
JD: Enhanced interaction between Hsp90 and raptor regulates mTOR
signaling upon T cell activation. Mol Immunol. 46:2694–2698. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Delgoffe GM, Kole TP, Zheng Y, Zarek PE,
Matthews KL, Xiao B, Worley PF, Kozma SC and Powell JD: The mTOR
kinase differentially regulates effector and regulatory T cell
lineage commitment. Immunity. 30:832–844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee WH, Kim GE, Hong KJ, Kim HS and Lee
GR: Insulin receptor substrate 1 signaling inhibits Foxp3
expression and suppressive functions in Treg cells through the
mTORC1 pathway. Int J Mol Sci. 24:25512023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pollizzi KN, Patel CH, Sun IH, Oh MH,
Waickman AT, Wen J, Delgoffe GM and Powell JD: mTORC1 and mTORC2
selectively regulate CD8+ T cell differentiation. J Clin
Invest. 125:2090–2108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zeng H and Chi H: mTOR signaling in the
differentiation and function of regulatory and effector T cells.
Curr Opin Immunol. 46:103–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tangye SG, Nguyen T, Deenick EK, Bryant VL
and Ma CS: Inborn errors of human B cell development,
differentiation, and function. J Exp Med. 220:e202211052023.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Staniek J and Rizzi M: Signaling
activation and modulation in extrafollicular B cell responses.
Immunol Rev. 330:e700042025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jones DD, Gaudette BT, Wilmore JR,
Chernova I, Bortnick A, Weiss BM and Allman D: mTOR has distinct
functions in generating versus sustaining humoral immunity. J Clin
Invest. 126:4250–4261. 2026. View Article : Google Scholar
|
|
61
|
Tsui C, Martinez-Martin N, Gaya M,
Maldonado P, Llorian M, Legrave NM, Rossi M, MacRae JI, Cameron AJ,
Parker PJ, et al: Protein kinase C-β dictates B cell fate by
regulating mitochondrial remodeling, metabolic reprogramming, and
heme biosynthesis. Immunity. 48:1144–1159.e5. 2018. View Article : Google Scholar
|
|
62
|
Benhamron S, Pattanayak SP, Berger M and
Tirosh B: mTOR activation promotes plasma cell differentiation and
bypasses XBP-1 for immunoglobulin secretion. Mol Cell Biol.
35:153–166. 2015. View Article : Google Scholar
|
|
63
|
Zhang S, Readinger JA, DuBois W,
Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ,
Sakakibara K, Patel J, et al: Constitutive reductions in mTOR alter
cell size, immune cell development, and antibody production. Blood.
117:1228–1238. 2011. View Article : Google Scholar
|
|
64
|
Iwata TN, Ramírez JA, Tsang M, Park H,
Margineantu DH, Hockenbery DM and Iritani BM: Conditional
disruption of raptor reveals an essential role for mTORC1 in B cell
development, survival, and metabolism. J Immunol. 197:2250–2260.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gaudette BT, Jones DD, Bortnick A, Argon Y
and Allman D: mTORC1 coordinates an immediate unfolded protein
response-related transcriptome in activated B cells preceding
antibody secretion. Nat Commun. 11:7232020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zeng Q, Qin S, Zhang H, Liu B, Qin J, Wang
X, Zhang R, Liu C, Dong X, Zhang S, et al: Rapamycin attenuates
BAFF-extended proliferation and survival via disruption of mTORC1/2
signaling in normal and neoplastic B-lymphoid cells. J Cell
Physiol. 233:516–529. 2018. View Article : Google Scholar
|
|
67
|
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang
F and Zhong R: Epidemiology of primary Sjögren's syndrome: A
systematic review and meta-analysis. Ann Rheum Dis. 74:1983–1989.
2015. View Article : Google Scholar
|
|
68
|
Mavragani CP and Moutsopoulos HM: The
geoepidemiology of Sjögren's syndrome. Autoimmun Rev. 9:A305–A310.
2010. View Article : Google Scholar
|
|
69
|
Baldini C, Pepe P, Quartuccio L, Priori R,
Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesti M, Tavoni A,
et al: Primary Sjogren's syndrome as a multi-organ disease: impact
of the serological profile on the clinical presentation of the
disease in a large cohort of Italian patients. Rheumatology
(Oxford). 53:839–844. 2014. View Article : Google Scholar
|
|
70
|
Brito-Zerón P, Theander E, Baldini C,
Seror R, Retamozo S, Quartuccio L, Bootsma H, Bowman SJ, Dörner T,
Gottenberg JE, et al: Early diagnosis of primary Sjögren's
syndrome: EULAR-SS task force clinical recommendations. Expert Rev
Clin Immunol. 12:137–156. 2016. View Article : Google Scholar
|
|
71
|
Weng MY, Huang YT, Liu MF and Lu TH:
Incidence and mortality of treated primary Sjogren's syndrome in
Taiwan: A population-based study. J Rheumatol. 38:706–708. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Maldini C, Seror R, Fain O, Dhote R,
Amoura Z, De Bandt M, Delassus JL, Falgarone G, Guillevin L, Le
Guern V, et al: Epidemiology of primary Sjögren's syndrome in a
French multiracial/multiethnic area. Arthritis Care Res (Hoboken).
66:454–463. 2014. View Article : Google Scholar
|
|
73
|
Brito-Zerón P, Acar-Denizli N, Zeher M,
Rasmussen A, Seror R, Theander E, Li X, Baldini C, Gottenberg JE,
Danda D, et al: Influence of geolocation and ethnicity on the
phenotypic expression of primary Sjögren's syndrome at diagnosis in
8310 patients: A cross-sectional study from the big data Sjögren
project consortium. Ann Rheum Dis. 76:1042–1050. 2017. View Article : Google Scholar
|
|
74
|
Singh AG, Singh S and Matteson EL: Rate,
risk factors and causes of mortality in patients with Sjögren's
syndrome: A systematic review and meta-analysis of cohort studies.
Rheumatology (Oxford). 55:450–460. 2016.
|
|
75
|
Ren Y, Cui G and Gao Y: Research progress
on inflammatory mechanism of primary Sjögren syndrome. Zhejiang Da
Xue Xue Bao Yi Xue Ban. 50:783–794. 2021.
|
|
76
|
Mavragani CP and Moutsopoulos HM:
Sjögren's syndrome: Old and new therapeutic targets. J Autoimmun.
110:1023642020. View Article : Google Scholar
|
|
77
|
Cai Y, Sun R, Wang R, Ren JG, Zhang W,
Zhao YF and Zhao JH: The activation of Akt/mTOR pathway by
bleomycin in Epithelial-to-mesenchymal transition of human
submandibular gland cells: A treatment mechanism of bleomycin for
mucoceles of the salivary glands. Biomed Pharmacother. 90:109–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Soypaçacı Z, Gümüş ZZ, Çakaloğlu F, Özmen
M, Solmaz D, Gücenmez S, Gercik Ö and Akar S: Role of the mTOR
pathway in minor salivary gland changes in Sjogren's syndrome and
systemic sclerosis. Arthritis Res Ther. 20:1702018. View Article : Google Scholar
|
|
79
|
Assinder SJ, Dong Q, Kovacevic Z and
Richardson DR: The TGF-beta, PI3K/Akt and PTEN pathways:
Established and proposed biochemical integration in prostate
cancer. Biochem J. 417:411–421. 2009. View Article : Google Scholar
|
|
80
|
Blokland SLM, Hillen MR, Wichers CGK,
Zimmermann M, Kruize AA, Radstake TRDJ, Broen JCA and van Roon JAG:
Increased mTORC1 activation in salivary gland B cells and T cells
from patients with Sjögren's syndrome: mTOR inhibition as a novel
therapeutic strategy to halt immunopathology? RMD Open.
5:e0007012019. View Article : Google Scholar
|
|
81
|
Zeng P, Jiang Z, Huang Z, Huang Y, Xu H,
Chen C and Ma W: PI3K/AKT/mTOR signaling pathway is downregulated
by runzaoling (RZL) in Sjögren's syndrome. Mediators Inflamm.
2022:72361182022. View Article : Google Scholar
|
|
82
|
Shields CA, McCalmon M, Ibrahim T, White
DL, Williams JM, LaMarca B and Cornelius DC: Placental
ischemia-stimulated T-helper 17 cells induce
preeclampsia-associated cytolytic natural killer cells during
pregnancy. Am J Physiol Regul Integr Comp Physiol. 315:R336–R343.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wang W, Sung N, Gilman-Sachs A and
Kwak-Kim J: T helper (Th) cell profiles in pregnancy and recurrent
pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh cells. Front Immunol.
11:20252020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Veldhoen M: Interleukin 17 is a chief
orchestrator of immunity. Nat Immunol. 18:612–621. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Barone F, Nayar S, Campos J, Cloake T,
Withers DR, Toellner KM, Zhang Y, Fouser L, Fisher B, Bowman S, et
al: IL-22 regulates lymphoid chemokine production and assembly of
tertiary lymphoid organs. Proc Natl Acad Sci USA. 112:11024–11029.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gao L, Dong Y, Lin R, Meng Y, Wu F and Jia
L: The imbalance of Treg/Th17 cells induced by perinatal bisphenol
A exposure is associated with activation of the PI3K/Akt/mTOR
signaling pathway in male offspring mice. Food Chem Toxicol.
137:1111772020. View Article : Google Scholar
|
|
87
|
Singh N and Cohen PL: The T cell in
Sjogren's syndrome: Force majeure, not spectateur. J Autoimmun.
39:229–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Qi W, Tian J, Wang G, Yan Y, Wang T, Wei
Y, Wang Z, Zhang G, Zhang Y and Wang J: Advances in cellular and
molecular pathways of salivary gland damage in Sjögren's syndrome.
Front Immunol. 15:14051262024. View Article : Google Scholar
|
|
89
|
Sisto M, Lisi S, Lofrumento DD, Frassanito
MA, Cucci L, D'Amore S, Mitolo V and D'Amore M: Induction of
TNF-alpha-converting enzyme-ectodomain shedding by pathogenic
autoantibodies. Int Immunol. 21:1341–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Crotty S: A brief history of T cell help
to B cells. Nat Rev Immunol. 15:185–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Nocturne G and Mariette X: B cells in the
pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol.
14:133–145. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhao J, Kubo S, Nakayamada S, Shimajiri S,
Zhang X, Yamaoka K and Tanaka Y: Association of plasmacytoid
dendritic cells with B cell infiltration in minor salivary glands
in patients with Sjögren's syndrome. Mod Rheumatol. 26:716–724.
2016. View Article : Google Scholar
|
|
93
|
Baturone R, Soto MJ, Márquez M, Macías I,
de Oca MM, Medina F, Chozas N, García-Pérez S and Girón-González
JA: Health-related quality of life in patients with primary
Sjögren's syndrome: Relationship with serum levels of
proinflammatory cytokines. Scand J Rheumatol. 38:386–389. 2009.
View Article : Google Scholar
|
|
94
|
Zong Y, Yang Y, Zhao J, Li L, Luo D, Hu J,
Gao Y, Wei L, Li N and Jiang L: Characterisation of macrophage
infiltration and polarisation based on integrated transcriptomic
and histological analyses in Primary Sjögren's syndrome. Front
Immunol. 14:12921462023. View Article : Google Scholar
|
|
95
|
Lu X, Li N, Zhao L, Guo D, Yi H, Yang L,
Liu X, Sun D, Nian H and Wei R: Human umbilical cord mesenchymal
stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits
via polarizing macrophages into an anti-inflammatory phenotype. Exp
Eye Res. 191:1079052020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Caprio M, Newfell BG, la Sala A, Baur W,
Fabbri A, Rosano G, Mendelsohn ME and Jaffe IZ: Functional
mineralocorticoid receptors in human vascular endothelial cells
regulate intercellular adhesion molecule-1 expression and promote
leukocyte adhesion. Circ Res. 102:1359–1367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Błochowiak KJ, Olewicz-Gawlik A,
Trzybulska D, Nowak-Gabryel M, Kocięcki J, Witmanowski H and
Sokalski J: Serum ICAM-1, VCAM-1 and E-selectin levels in patients
with primary and secondary Sjögren's syndrome. Adv Clin Exp Med.
26:835–842. 2017. View Article : Google Scholar
|
|
98
|
Silver N, Proctor GB, Arno M and Carpenter
GH: Activation of mTOR coincides with autophagy during
ligation-induced atrophy in the rat submandibular gland. Cell Death
Dis. 1:e142010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Maleki-Fischbach M, Kastsianok L, Koslow M
and Chan ED: Manifestations and management of Sjögren's disease.
Arthritis Res Ther. 26:432024. View Article : Google Scholar
|
|
100
|
Price EJ, Rauz S, Tappuni AR, Sutcliffe N,
Hackett KL, Barone F, Granata G, Ng WF, Fisher BA, Bombardieri M,
et al: The British society for rheumatology guideline for the
management of adults with primary Sjögren's syndrome. Rheumatology
(Oxford). 56:e24–e48. 2017. View Article : Google Scholar
|
|
101
|
Negrini S, Emmi G, Greco M, Borro M,
Sardanelli F, Murdaca G, Indiveri F and Puppo F: Sjögren's
syndrome: A systemic autoimmune disease. Clin Exp Med. 22:9–25.
2022. View Article : Google Scholar :
|
|
102
|
Yura Y and Hamada M: Outline of salivary
gland pathogenesis of Sjögren's syndrome and current therapeutic
approaches. Int J Mol Sci. 24:111792023. View Article : Google Scholar
|
|
103
|
Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang
Z, Yang W, Guo Y and Lin L: Systemic lupus erythematosus:
Pathogenesis and targeted therapy. Mol Biomed. 5:542024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Shao Y, Fu J, Zhan T, Ye L and Yu C:
Fangchinoline inhibited proliferation of neoplastic B-lymphoid
cells and alleviated Sjögren's syndrome-like responses in NOD/Ltj
mice via the Akt/mTOR pathway. Curr Mol Pharmacol. 15:969–979.
2022. View Article : Google Scholar
|
|
105
|
Zhou KG, Huang YB, Zhu ZW, Jiang M, Jin
LJ, Guan Q, Tian LL and Zhang JX: Mesencephalic astrocyte-derived
neurotrophic factor inhibits neuroinflammation through
autophagy-mediated α-synuclein degradation. Arch Gerontol Geriatr.
131:1057382025. View Article : Google Scholar
|
|
106
|
Cheng D, Zhou T, Liu H, Li L, Xuan Y,
Huang L, Liu Y, Zhang X, Wei W and Wu H: MANF inhibits Sjögren's
syndrome salivary gland epithelial cell apoptosis and antigen
expression of Ro52/SSA through endoplasmic reticulum
stress/autophagy pathway. Int Immunopharmacol. 122:1105822023.
View Article : Google Scholar
|
|
107
|
Lyu T, Jiang H, Zeng L, Liu S, He C, Luo
C, Qiao L, Zhao Y and Chen H: Iguratimod suppresses Tfh cell
differentiation in primary Sjögren's syndrome patients through
inhibiting Akt/mTOR/STAT3 signaling. Arthritis Res Ther.
25:1522023. View Article : Google Scholar
|
|
108
|
Ju Y, Edman MC, Guo H, Janga SR, Peddi S,
Louie SG, Junge JA, MacKay JA and Hamm-Alvarez SF: Intralacrimal
sustained delivery of rapamycin shows therapeutic effects without
systemic toxicity in a mouse model of autoimmune dacryoadenitis
characteristic of Sjögren's syndrome. Biomacromolecules.
22:1102–1114. 2021. View Article : Google Scholar
|
|
109
|
Kim J, Kim YS and Park SH: Metformin as a
treatment strategy for Sjögren's syndrome. Int J Mol Sci.
22:72312021. View Article : Google Scholar
|
|
110
|
Kim JW, Kim SM, Park JS, Hwang SH, Choi J,
Jung KA, Ryu JG, Lee SY, Kwok SK, Cho ML and Park SH: Metformin
improves salivary gland inflammation and hypofunction in murine
Sjögren's syndrome. Arthritis Res Ther. 21:1362019. View Article : Google Scholar
|
|
111
|
Zhang S and Li J, Nong X, Zhan Y, Xu J,
Zhao D, Ma C, Wang Y, Li Y, Li Z and Li J: Artesunate combined with
metformin ameliorate on diabetes-induced xerostomia by mitigating
superior salivatory nucleus and salivary glands injury in type 2
diabetic rats via the PI3K/AKT pathway. Front Pharmacol.
12:7746742021. View Article : Google Scholar
|
|
112
|
Nayar S, Campos J, Smith CG, Iannizzotto
V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ,
Brewer C, et al: Phosphatidylinositol 3-kinase delta pathway: A
novel therapeutic target for Sjögren's syndrome. Ann Rheum Dis.
78:249–260. 2019. View Article : Google Scholar :
|
|
113
|
Scuron MD, Fay BL, Connell AJ, Oliver J
and Smith PA: The PI3Kδ inhibitor parsaclisib ameliorates pathology
and reduces autoantibody formation in preclinical models of
systemic lupus erythematosus and Sjӧgren's syndrome. Int
Immunopharmacol. 98:1079042021. View Article : Google Scholar
|
|
114
|
Kaneko Y, Fukahori H, Yamagami K,
Kawashima T, Ito M, Akamatsu M, Marui T, Kato K, Takahashi F and
Morokata T: Effects of AS2819899, a novel selective PI3Kδ
inhibitor, in a NZB/W F1 mouse lupus-like nephritis model. Int
Immunopharmacol. 87:1067642020. View Article : Google Scholar
|
|
115
|
Yamaguchi J, Isnard P, Robil N, de la
Grange P, Hoguin C, Schmitt A, Hummel A, Megret J, Goudin N, Luka
M, et al: PIK3CA inhibition in models of proliferative
glomerulonephritis and lupus nephritis. J Clin Invest.
134:e1764022024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Juarez M, Diaz N, Johnston GI, Nayar S,
Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher
BA, et al: A phase 2 randomized, double-blind, placebo-controlled,
proof-of-concept study of oral seletalisib in primary Sjögren's
syndrome. Rheumatology (Oxford). 60:1364–1375. 2021. View Article : Google Scholar
|
|
117
|
Wu C, Wang Q, Xu D, Li M and Zeng X:
Sirolimus for patients with connective tissue disease-related
refractory thrombocytopenia: A single-arm, open-label clinical
trial. Rheumatology (Oxford). 60:2629–2634. 2021. View Article : Google Scholar
|
|
118
|
Du H, Su W, Su J, Hu J, Wu D, Long W and
Zhu J: Sirolimus for the treatment of patients with refractory
connective tissue disease-related thrombocytopenia: A pilot study.
Rheumatology (Oxford). 63:79–84. 2024. View Article : Google Scholar
|
|
119
|
Li X, Su L, Sun X, Li X, Tian Z, Liao Q,
Sun W and Zhao Y: Effect of sirolimus on connective tissue disease
related refractory thrombocytopenia: Clinical efficacy and
immunomodulatory mechanism. Postepy Dermatol Alergol. 42:494–501.
2025.PubMed/NCBI
|
|
120
|
Jiang N, Li M, Zhang H, Duan X, Li X, Fang
Y, Li H, Yang P, Luo H, Wang Y, et al: Sirolimus versus tacrolimus
for systemic lupus erythematosus treatment: Results from a
real-world CSTAR cohort study. Lupus Sci Med. 9:e0006172022.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Bai W, Peng L, Gui Y, Chen Y, Duan X, Li
X, Zhang H, Huo Y, Xu J, Yang P, et al: Sirolimus versus
mycophenolate mofetil for the treatment of lupus nephritis: Results
from a real-world CSTAR cohort study. Rheumatol Immunol Res.
6:80–89. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Mariette X, Barone F, Baldini C, Bootsma
H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang
K, et al: A randomized, phase II study of sequential belimumab and
rituximab in primary Sjögren's syndrome. JCI Insight.
7:e1630302022. View Article : Google Scholar
|
|
123
|
Moysidou GS, Garantziotis P, Sentis G,
Nikoleri D, Malissovas N, Nikoloudaki M, Stergioti EM, Polia S,
Paschalidis N, Filia A, et al: Molecular basis for the
disease-modifying effects of belimumab in systemic lupus
erythematosus and molecular predictors of early response: Blood
transcriptome analysis implicates the innate immunity and DNA
damage response pathways. Ann Rheum Dis. 84:262–273. 2025.
View Article : Google Scholar : PubMed/NCBI
|
